Why Is Acurx Pharmaceuticals Stock Falling Thursday? - Acurx Pharmaceuticals (NASDAQ:ACXP)

Core Viewpoint - Acurx Pharmaceuticals Inc. shares experienced a significant pullback in premarket trading after a substantial rally, indicating potential overbought conditions in the stock market [1][2]. Clinical Update - Acurx Pharmaceuticals announced a new trial for ibezapolstat targeting patients with recurrent C. difficile infection (rCDI), reporting a 96% clinical cure rate from Phase 2 data [3]. - Enrollment for the new study is set to begin in the fourth quarter [3]. Financial Results - The company is expected to report a loss per share of $1.00 for the fourth quarter of 2025, a decrease from a loss of $3.40 per share a year earlier [4]. Strategic Developments - Acurx is advancing into Phase 3 international studies, contingent on funding, and ibezapolstat has received FDA Fast Track and Qualified Infectious Disease Product designations [5]. Technical Analysis - The stock is trading 162.5% above its 20-day simple moving average (SMA) and 48.3% above its 100-day SMA, indicating a strong short-term performance [6]. - Over the past 12 months, shares have declined by 35.16%, and the stock is currently closer to its 52-week lows of $1.33 than its highs of $21.00 [6]. Price Action - During premarket trading, Acurx Pharmaceuticals shares were down 12.95% at $5.24, with key resistance identified at $5.50 and key support at $5.00 [7].